Category:Osteoporosis medications: Difference between revisions
Category page
More actions
Create canonical category-page article (history-first) |
Rewrite per canonical category-page spec (history-first article) |
||
| Line 11: | Line 11: | ||
The duration-of-treatment question is one of the central clinical decisions in osteoporosis care. For oral bisphosphonates, a five-year course followed by a "medicine holiday" of 2-5 years (during which antifracture benefit persists because of the long bone half-life of the bisphosphonate) is the standard for most patients; high-risk patients may continue beyond 5 years. For annual intravenous zoledronate, 3 years followed by a holiday is standard, with 6 years for higher-risk patients. For denosumab, no medicine holiday is recommended: abrupt discontinuation produces a rebound of bone resorption with multiple vertebral fractures within months, and patients who discontinue denosumab for any reason must be transitioned to a bisphosphonate to lock in the gains. For teriparatide and abaloparatide, the 24-month lifetime treatment limit (osteosarcoma concern from rat lifetime exposure, not directly seen in humans but the regulatory caution remains) defines the duration; sequential transition to an antiresorptive is required to maintain the gains. For romosozumab, 12 months of treatment is the maximum (the ARCH trial endpoint), again followed by antiresorptive maintenance. | The duration-of-treatment question is one of the central clinical decisions in osteoporosis care. For oral bisphosphonates, a five-year course followed by a "medicine holiday" of 2-5 years (during which antifracture benefit persists because of the long bone half-life of the bisphosphonate) is the standard for most patients; high-risk patients may continue beyond 5 years. For annual intravenous zoledronate, 3 years followed by a holiday is standard, with 6 years for higher-risk patients. For denosumab, no medicine holiday is recommended: abrupt discontinuation produces a rebound of bone resorption with multiple vertebral fractures within months, and patients who discontinue denosumab for any reason must be transitioned to a bisphosphonate to lock in the gains. For teriparatide and abaloparatide, the 24-month lifetime treatment limit (osteosarcoma concern from rat lifetime exposure, not directly seen in humans but the regulatory caution remains) defines the duration; sequential transition to an antiresorptive is required to maintain the gains. For romosozumab, 12 months of treatment is the maximum (the ARCH trial endpoint), again followed by antiresorptive maintenance. | ||
The supportive-care medicines complete the regimen. Calcium supplementation (1000-1200 mg per day, including dietary sources) and vitamin D supplementation (800-2000 IU per day, with a 25-hydroxyvitamin D target above 30 ng/mL) are foundational and are co-prescribed with every active osteoporosis regimen; the supplementation may be insufficient as monotherapy for established osteoporosis but is necessary to optimise the effect of antiresorptive and anabolic medicines. Physical activity (weight-bearing exercise, resistance training, balance training to reduce fall risk), fall-risk modification ( | The supportive-care medicines complete the regimen. Calcium supplementation (1000-1200 mg per day, including dietary sources) and vitamin D supplementation (800-2000 IU per day, with a 25-hydroxyvitamin D target above 30 ng/mL) are foundational and are co-prescribed with every active osteoporosis regimen; the supplementation may be insufficient as monotherapy for established osteoporosis but is necessary to optimise the effect of antiresorptive and anabolic medicines. Physical activity (weight-bearing exercise, resistance training, balance training to reduce fall risk), fall-risk modification (review of sedating medicines, home-safety assessment), and avoidance of bone-toxic medicines (chronic glucocorticoids, aromatase inhibitors in selected patients, GnRH agonist therapy in prostate cancer) are part of standard non-pharmacological management. | ||
== Classes indexed == | == Classes indexed == | ||